Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Clinical Study on the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of ScTIL Injection (Gene Modified Tumor Infiltrating Lymphocytes) Alone and in Combination With B Lymphocyte Adjuvant in the Treatment of Digestive System Malignant Solid Tumors

NCT05730361 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT05730361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05730361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Clinical Study on the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of ScTIL Injection (Gene Modified Tumor Infiltrating Lymphocytes) Alone and in Combination With B Lymphocyte Adjuvant in the Treatment of Digestive System Malignant Solid Tumors
Lead sponsor
Peking University
Phase
Phase 1
Overall status
Unknown status
Start date
February 28, 2023
Completion date
August 31, 2024
Enrollment
48 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

digestive system malignant solid tumors